

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Adress COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/933,316	08/20/2001	Stephen C Porter	29985/01-185	7064
4743 7	590 05/07/2003			
MARSHALL, GERSTEIN & BORUN 6300 SEARS TOWER 233 SOUTH WACKER CHICAGO, IL 60606-6357			EXAMINER	
			SHARAREH, SHAHNAM J	
CHICAGO, ID 00000-0557			ART UNIT	PAPER NUMBER
			1617	
			DATE MAILED: 05/07/2003	6

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	09/933,316	PORTER, STEPHEN C				
Office Action Summary	Examiner	Art Unit				
	Shahnam Sharareh	1617				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, may a reply y within the statutory minimum of thirty (30 will apply and will expire SIX (6) MONTHS , cause the application to become ABAND	be timely filed 1) days will be considered timely. 3 from the mailing date of this communication. 2 DONED (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on <u>06 February 2003</u> .						
2a) This action is FINAL . 2b) Th	This action is FINAL . 2b) This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) 1-37 is/are pending in the application.						
5) Claim(s) is/are allowed.	4a) Of the above claim(s) <u>29-37</u> is/are withdrawn from consideration.					
6) Claim(s) is/are rejected.						
7) Claim(s) is/are rejected.						
_	8)⊠ Claim(s) 1-28 are subject to restriction and/or election requirement.					
Application Papers	sicotion requirement.					
9) The specification is objected to by the Examine	r.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Infor	mary (PTO-413) Paper No(s) mal Patent Application (PTO-152)				

Application/Control Number: 09/933,316

Art Unit: 1617

Election/Restrictions

Applicant's election with traverse of Group I in Paper No. 5 filed on February 6, 2003 is acknowledged. The traversal is on the ground(s) that the process of tissue bulking of claims of Group II cannot be practiced by another materially different product for the compositions of the claims of Group I. Applicant further argues that Examiner has no nown an example of such requirement because Evans in US Patent 5,702,361 does not disclose a method of tissue bulking (see Response at page 1-2).

This argument is not found persuasive because Evens teaches methodologies that are encompassed by the instant tissue bulking methods. Tissue bulking as defined in the instant specification at page 10, line 14, refers to methods of introducing a non-naturally occurring composition into muscular, connective or fatty tissue to increase the volume of such tissues. Evans teaches the introduction of his compositions into connective tissues such as fallopian tubes or the vas deferens of test subjects (see col 10, lines 35-39). Once solidified, Evens compositions cause an increase in the volume of such tissues. Therefore, Evens teaches obtaining patentably distinct non-naturally occurring compositions and introducing said non-naturally occurring composition into muscular, connective or fatty tissues encompassed by the meaning of the claimed methods of tissue bulking.

Moreover, in requiring a restriction, the burden of examiner is to merely provide an example, but the example need not even be documented. Subsequently, Applicant has the burden to prove or provide a convincing argument that the alternative product cannot be used to practice the asserted process (see MPEP 806.05 (h)). In the instant

Application/Control Number: 09/933,316

Art Unit: 1617

case, Applicants have neither provided any evidence nor argued that Evans compositions cannot cause tissue bulking. Thus, the requirement is still deemed proper and is therefore made FINAL.

Claims 29-37 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 5.

This application contains claims 29-37 drawn to an invention nonelected with traverse in Paper No. 5. A complete reply to the final rejection must include cancelation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Election of Species

Examination of claims 1-28 requires an election of species for the following reasons. Claim 1-28 are are generic to a plurality of disclosed patentably distinct species comprising non-cyanoacrylate rheology modifying agents wherein said agents are selected from a group consisting of a polymer (claims 1-5, 7-11, 15-28), inorganic particulate material (claims 1-3, 6, 12-28) and a mixture thereof. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over

Application/Control Number: 09/933,316

Art Unit: 1617

the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

A telephone call was made to Mark Hopkins on May 2, 2003 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shahnam Sharareh whose telephone number is 703-306-5400. The examiner can normally be reached on 8:30 am - 6:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan, PhD can be reached on 703-308-1877. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1123.

May 5, 2003

Page 4